Rivaroxaban, also known as BAY 59-7939, is an oral anticoagulant invented and manufactured by Bayer; in a number of countries it is marketed as Xarelto. If approved by the United States FDA, it will be marketed by Ortho-McNeil Pharmaceutical. It is the first available orally active direct factor Xa inhibitor. Rivaroxaban is well absorbed from the gut and maximum inhibition of factor Xa occurs four hours after a dose. The effects lasts 8–12 hours, but factor Xa activity does not return to normal within 24 hours so once-daily dosing is possible.
Properties:
Density: 1.46g/cm3
Boiling Point: 732.6ºC at 760mmHg
Melting Point: 228-229°C
Flash Point: 396.9ºC
Refractive Index: 1.633
Factor Xa Related Products:
Apixaban; Fondaparinux sodium; Betrixaban; Edoxaban tosylate; Milvexian